Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Simona Di Giambenedetto and Roberto Cauda.
Simona Di Giambenedetto
Connection Strength
2.074
Roberto Cauda
  1. Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. Infez Med. 2021 Mar 01; 29(1):54-64.
    View in: PubMed
    Score: 0.233
  2. No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy. Clin Microbiol Infect. 2020 Dec 02.
    View in: PubMed
    Score: 0.229
  3. The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic. HIV Med. 2021 01; 22(1):e3-e4.
    View in: PubMed
    Score: 0.225
  4. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020 10; 92(10):1787-1788.
    View in: PubMed
    Score: 0.222
  5. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Res Clin Pract. 2019 Sep 03; 1-7.
    View in: PubMed
    Score: 0.210
  6. Liver fibrosis is associated with cognitive impairment in people living with HIV. Infection. 2019 Aug; 47(4):589-593.
    View in: PubMed
    Score: 0.202
  7. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
    View in: PubMed
    Score: 0.178
  8. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. J Chemother. 2017 Oct; 29(5):299-307.
    View in: PubMed
    Score: 0.174
  9. People Living with HIV in the COVID-19 Era: A Case Report. AIDS Res Hum Retroviruses. 2021 04; 37(4):253-254.
    View in: PubMed
    Score: 0.056
  10. Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive. J Infect. 2021 01; 82(1):159-198.
    View in: PubMed
    Score: 0.055
  11. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Int J Antimicrob Agents. 2020 Aug; 56(2):106017.
    View in: PubMed
    Score: 0.055
  12. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
    View in: PubMed
    Score: 0.048
  13. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 07 01; 73(7):1949-1954.
    View in: PubMed
    Score: 0.048
  14. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. Antivir Ther. 2018; 23(2):139-148.
    View in: PubMed
    Score: 0.047
  15. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother. 2017 07 01; 72(7):2055-2059.
    View in: PubMed
    Score: 0.045
  16. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.